For personal use only Riding the Waves of Change The winds and the - - PowerPoint PPT Presentation

for personal use only
SMART_READER_LITE
LIVE PREVIEW

For personal use only Riding the Waves of Change The winds and the - - PowerPoint PPT Presentation

For personal use only Riding the Waves of Change The winds and the waves are always on the side of the ablest navigators. By Edward Gibbon, Historian (1737-1794) Investor Presentation 16 Nov 2012 2012 Key Financial Performance For


slide-1
SLIDE 1

Investor Presentation 16 Nov 2012 Riding the Waves of Change

“The winds and the waves are always on the side of the ablest navigators.” By Edward Gibbon, Historian (1737-1794)

For personal use only

slide-2
SLIDE 2

2012 Key Financial Performance

Net Profit S$8m EPS Sgp 3.69 cts Dividends per share Aus 1 cts (5.6% yield) ROE 9.7% NTA per share Sgp 34.22 cts Net Working Capital S$42.42m Cash S$24.45m

For personal use only

slide-3
SLIDE 3

95 127 135 108 147 131 7.8 8.7 10.0 10.1 14.1 7.8 2 4 6 8 10 12 14 16 18 20 40 60 80 100 120 140 160 2007 2008 2009 2010 2011 2012

Millions Millions

Revenue NPAT

ZICOM GROUP LTD

Consolidated Revenue Vs. NPAT Trend Revenue Net Profit

S$'million

Consolidated Revenue Vs. NPAT Trend

For personal use only

slide-4
SLIDE 4

Revenue by Segment

Offshore Marine, Oil & Gas, $34.35m, 26% Construction , $57.39m, 44% Precision Engineering & Automation, $34.90m, 27% Industrial & Mobile, $3.20m, 3% Offshore Marine, Oil & Gas, $58.33m, 40% Construction , $55.23m, 37% Precision Engineering & Automation, $30.65m, 21% Industrial & Mobile, $3.21m, 2%

FY2012 FY2011

For personal use only

slide-5
SLIDE 5

Earnings Record

FY07 FY08 FY09 FY10 FY11 FY12 $7.76 $8.70 $10.04 $10.14 $14.09 $7.84 FY07 FY08 FY09 FY10 FY11 FY12 4.31 4.60 4.86 4.82 6.62 3.69

Net Profit (S$m) EPS (Sgp cents)

For personal use only

slide-6
SLIDE 6

ROE & Dividend

FY07 FY08 FY09 FY10 FY11 FY12

0.20 0.80 0.60 0.85 1.00 1.00

Dividend (Aust cents)

FY07 FY08 FY09 FY10 FY11 FY12

28.6% 21.5% 19.3% 16.4% 19.5% 9.7%

ROE

For personal use only

slide-7
SLIDE 7

FY2012 Review

  • (Marine) Slow demand due to rationalization of shipbuilding

industry

  • (Oil & Gas) Challenges in integrating cross culture engineering

team and execution of project

  • (Construction) Resilient demand for construction equipment in

Asia

  • (Precision Engineering & Automation) Strengthened

positioning in niche areas and value added activities.

For personal use only

slide-8
SLIDE 8

General Business Outlook

For personal use only

slide-9
SLIDE 9

Offshore Marine

  • Outlook
  • Sustainable resurgence in

demand for deck machinery.

  • Well positioned to participate in

supply to high end deep sea

  • perations
  • Sustainable growth prospects

For personal use only

slide-10
SLIDE 10

Oil & Gas

  • Outlook
  • Improved capabilities in engineering & project management
  • Strategic alliances with international partners
  • Strengthened growth prospects

For personal use only

slide-11
SLIDE 11

Construction

  • Outlook
  • Consolidated production in Thailand

for mixers enable us to maintain competitiveness.

  • Refocusing on rental of foundation

equipment to support any slowdown in construction activities

  • Strong financial position enables us

to maintain competitive position

For personal use only

slide-12
SLIDE 12

Precision Engineering & Automation

  • Outlook
  • Increased recognition by MNCs as competitive contract

manufacturer.

  • Strong capabilities in new product introduction
  • Sustainable outlook and demand.

For personal use only

slide-13
SLIDE 13

Investments in Disruptive Technologies with Prospects in Exponential Growth

For personal use only

slide-14
SLIDE 14

Orion Flip Chip Thermal Bonder

  • Secured order for 1st commercial unit by China’s leading chip

assembler

  • Take off in orders has commenced
  • Industry projection for flip chips to increase 10% due to

demand for handheld devices

For personal use only

slide-15
SLIDE 15

Curiox Drug Discovery Bio-Instrumentation

  • DropArray technology validated by Genentech USA,

pioneers in biotechnology.

  • Technology proven to save costs in drug discovery

processes by more than 50%.

  • Currently technology being trialed by 10 key players in USA

and Europe with strong prospect of sales crystallizing

For personal use only

slide-16
SLIDE 16

Biobot Surgical Robot

  • Obtained regulatory approvals

with FDA, CE, TGA, and DOH

  • Engineering refinements

completed, commercial unit expected to be ready 1Q2013

  • Commercialization target in

2Q2013

For personal use only

slide-17
SLIDE 17

Thank You

For personal use only